Clinical trials
Phase 2 Ovarian Neoplasms trials in Belgium
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
48 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 8 |
| 2009 | 2 |
| 2010 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 5 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 31 |
| Recruiting | 7 |
| Active, not recruiting | 6 |
| Terminated | 4 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AbbVie | 4 |
| AstraZeneca | 3 |
| Eli Lilly and Company | 3 |
| European Organisation for Research and Treatment of Cancer - EORTC | 3 |
| Bayer | 2 |
| Corcept Therapeutics | 2 |
| Hoffmann-La Roche | 2 |
| Universitaire Ziekenhuizen KU Leuven | 2 |
| ARCAGY/ GINECO GROUP | 1 |
| Aprea Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ovarian Neoplasms | 48 |
| Fallopian Tube Neoplasms | 10 |
| Neoplasms | 8 |
| Breast Neoplasms | 5 |
| Endometrial Neoplasms | 5 |
| Peritoneal Neoplasms | 5 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Carcinoma, Ovarian Epithelial | 4 |
| Melanoma | 4 |
| Head and Neck Neoplasms | 3 |
Trials
Showing 1 to 25 of 48. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.